SCHEMBL147709 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	AAK1	Q2M2I8	3/20	0.50

▸	MAPT	P10636	3/20	0.48

▸	ABCB1	P08183	2/20	0.48

▸	KDM4E	B2RXH2	3/20	0.46

▸	ALDH1A1	P00352	2/20	0.46

▸	GAA	P10253	1/20	0.46

▸	HPGD	P15428	1/20	0.46

▸	PDE4B	Q07343	2/20	0.46

▸	TP53	P04637	1/20	0.46

▸	MAPK1	P28482	2/20	0.45

▸	SMN1; SMN2	Q16637	3/20	0.45

▸	MEN1	O00255	1/20	0.45

▸	NPC1	O15118	1/20	0.45

▸	RAB9A	P51151	1/20	0.45

▸	KMT2A	Q03164	1/20	0.45

▸	POLB	P06746	2/20	0.44

▸	TSHR	P16473	1/20	0.44

▸	PDE4A	P27815	1/20	0.42

▸	PDE4C	Q08493	1/20	0.42

▸	PDE4D	Q08499	1/20	0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL6686004	0.91	PDE4B (0.44)	AAK1MAPTALDH1A1PDE4BMAPK1
SCHEMBL6656468	0.88	KMT2A (0.45)	MAPTALDH1A1PDE4BTP53SMN1; SMN2
SCHEMBL144459	0.87	ABCB1 (0.50)	AAK1MAPTABCB1KDM4EALDH1A1
SCHEMBL6365295	0.87	PDE4B (0.58)	AAK1MAPTABCB1KDM4EALDH1A1
SCHEMBL6962406	0.87	PDE4B (0.42)	MAPTALDH1A1HPGDPDE4BTP53
SCHEMBL144435	0.86	AAK1 (0.51)	AAK1MAPTABCB1KDM4EALDH1A1
SCHEMBL6658910	0.86	SMN1; SMN2 (0.46)	MAPTKDM4EALDH1A1GAAHPGD
SCHEMBL6656003	0.86	PDE4B (0.44)	MAPTPDE4BPOLBPDE4APDE4C
SCHEMBL146176	0.86	PDE4B (0.50)	AAK1MAPTABCB1KDM4EALDH1A1
SCHEMBL6686322	0.85	KMT2A (0.47)	MAPTALDH1A1HPGDPDE4BTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	MERK PANTENT GMBH (DE)	2005-03-31	—	—	US	claimed
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	MERCK PATENT GMBH (DE)	2004-12-23	—	—	US	claimed
EP-1463509-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GmbH (DE)	2004-10-06	—	—	EP	claimed
EP-1368035-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GmbH (DE)	2003-12-10	—	—	EP	claimed
WO-2003037349-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GMBH (DE)	2003-05-08	—	—	WO	claimed
WO-2002072103-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GMBH (DE)	2002-09-19	—	—	WO	claimed
US-20140221455-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	Verva Pharmaceuticals, Inc. (AU)	2014-08-07	—	—	US	disclosed
US-20120059047-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	VERVA PHARMACEUTICALS PTY LTD (AU)	2012-03-08	—	—	US	disclosed
US-20050282733-A1	Differentiation modulating agents and uses therefor	VERVA PHARMACEUTICALS PTY LTD (AU)	2005-12-22	—	—	US	disclosed
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	MERK PANTENT GMBH (DE)	2005-03-31	—	—	US	disclosed
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	MERCK PATENT GMBH (DE)	2004-12-23	—	—	US	disclosed
US-20040235845-A1	Use of phosphodiesterase iv inhibitors	MERCK PATENT GESSELSCHAFT MIT BESCHRANKTER HAFTUNG (DE)	2004-11-25	—	—	US	disclosed
EP-1463509-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GmbH (DE)	2004-10-06	—	—	EP	disclosed
EP-1368035-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GmbH (DE)	2003-12-10	—	—	EP	disclosed
WO-2003037349-A1	TYPE 4 PHOSPHODIESTERASE INHIBITORS AND USES THEREOF	MERCK PATENT GMBH (DE)	2003-05-08	—	—	WO	disclosed
WO-2003032993-A1	USE OF PHOSPHORODIESTERASE IV INHIBITORS	MERCK PATENT GMBH (DE)	2003-04-24	—	—	WO	disclosed
EP-0763534-B1	Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors	MERCK PATENT GMBH (DE)	2003-02-26	—	—	EP	disclosed
WO-2002072103-A1	USE OF TYPE 4 PHOSPHODIESTERASE INHIBITORS IN MYOCARDIAL DISEASES	MERCK PATENT GMBH (DE)	2002-09-19	—	—	WO	disclosed
US-5859008-A	Arylalkyl diazinones	MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE)	1999-01-12	—	—	US	disclosed
EP-0763534-A1	Arylalkyl-diazinone derivatives as phosphodiesterase IV inhibitors	MERCK PATENT GmbH (DE)	1997-03-19	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120059047-A1	DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR	FGF1, FABP4, FGF2	AAK1 960/4885MAPT 4367/4885ABCB1 4804/4885
US-20040235845-A1	Use of phosphodiesterase iv inhibitors	PDE4A, PDE3A, PDE3B	AAK1 2795/4885MAPT 3595/4885ABCB1 1255/4885
US-20050282733-A1	Differentiation modulating agents and uses therefor	FGF1, FABP4, FGF2	AAK1 960/4885MAPT 4367/4885ABCB1 4804/4885
US-20050070529-A1	Use of type 4 phosphodiesterase inhibitors in myocardial diseases	PDE4A, PDE4B, PDE12	AAK1 3113/4885MAPT 4264/4885ABCB1 1476/4885
US-20040259863-A1	Type 4 phosphodiesterase inhibitors and uses thereof	PDE4A, PDE4B, PDE4C	AAK1 3520/4885MAPT 3911/4885ABCB1 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.